Top Markets
Coin of the day
PCL, Inc. PCL, Inc.

PCL, Inc.

241820
株式のランク #31786
PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic... PCL, Inc. specializes in providing sophisticated multiplex in vitro diagnostic (IVD) solutions, encompassing both diagnostic products and specialized platform services. The company's primary offerings include comprehensive multiplex kits designed to detect antibodies to Human Immunodeficiency Virus (HIV) types 1 and 2, Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and Human T-lymphotropic Virus (HTLV) types 1 and 2. These kits also identify specific antigens such as HIV p24, HCV core, and HBV surface markers in human serum or plasma samples. In addition to these, PCL markets Ai, a rapid diagnostic test kit capable of typing influenza A and B strains; Cancer6, a screening kit for multiple tumor biomarkers; and the sciLINER LATERAL FLOW DISPENSER, an advanced dispensing device for membrane materials featuring active visual drop volume control. Beyond its product portfolio, PCL offers valuable platform services. These include a sol-gel spotting service, which immobilizes client-specified materials using the proprietary SolB reagent, and an SG ID service, providing customers with identified molecules of interest securely immobilized within the SolB reagent. PCL, Inc. is headquartered in Seoul, South Korea.
株価
$0.21291741
最終同期: 2025-04-18
時価総額
$12.07M
変化(1日)
0.00%
変化(1年)
0.00%
KR
取引 PCL, Inc. (241820)

カテゴリー

PCL, Inc.(241820)の利益
Sep 2025 時点の利益 TTM: $-33.90M
PCL, Inc. の最新の財務報告によると、同社の現在の利益は $-33.90M です。2023 年には $-15.73M の利益を上げ、これは 2022 年の利益 $-3.18M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
PCL, Inc. の利益の推移(2015 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-33.90M -5.68%
2024 $-35.94M 128.48%
2023 $-15.73M 394.91%
2022 $-3.18M -88.07%
2021 $-26.64M -248.25%
2020 $17.97M -360.49%
2019 $-6.90M 33.10%
2018 $-5.18M 42.76%
2017 $-3.63M 87.03%
2016 $-1.94M 22.38%
2015 $-1.59M 0.00%
同業他社の利益
企業 利益 利益の差
$7.51B -22,254.56%
US
$5.15B -15,284.62%
US
$5.56B -16,508.71%
IE
$3.86B -11,488.46%
US
$1.42B -4,281.37%
US